{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:29:41Z","timestamp":1766122181058,"version":"3.48.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Patients with cancer-associated venous thromboembolism (VTE) often require prolonged anticoagulation because malignancy and chemotherapy can persist for months to years, sustaining both thrombotic and bleeding risks. While full-dose apixaban (5 mg twice daily) is recommended for secondary prevention, extended use may increase bleeding in this vulnerable population. Reducing the dose to 2.5 mg twice daily after six months of full-dose treatment has been proposed to lower bleeding risk without compromising protection against recurrent VTE. To clarify the safety and efficacy of this strategy, we conducted a meta-analysis of randomized controlled trials comparing reduced- versus standard-dose apixaban for extended therapy in patients with cancer-associated VTE. The study followed PRISMA guidelines and was registered in PROSPERO (CRD420251026337). Hazard ratios and risk ratios with 95% confidence intervals were pooled using a random-effects model, and evidence certainty was assessed with GRADE. Two randomized trials comprising 2,126 patients (EVE, n = 360; API-CAT, n = 1,766) met inclusion criteria. The composite outcome of recurrent VTE with bleeding showed a significantly lower risk with reduced-dose apixaban (risk ratio 0.79, 95% CI 0.65\u20130.96; I\n                    <jats:sup>2<\/jats:sup>\n                    = 0%), and the composite of major and clinically relevant nonmajor bleeding was also reduced (HR 0.75 (95% CI 0.63\u20130.88; I\n                    <jats:sup>2<\/jats:sup>\n                    = 0%). No significant differences were observed for recurrent VTE, major bleeding, clinically relevant nonmajor bleeding, mortality, deep-vein thrombosis, or pulmonary embolism. These findings indicate that reduced-dose apixaban after the initial six months of anticoagulation decreases bleeding without loss of efficacy, supporting dose de-escalation as a safe, evidence-based approach for extended anticoagulation in cancer-associated VTE.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier PROSPERO CRD420251026337.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1690984","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:17:46Z","timestamp":1766121466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced versus standard dose apixaban for secondary prevention of cancer-associated venous thromboembolism: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Vasu","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardit","family":"Feinaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devesh","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Ash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad B.","family":"Boozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Breslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Trube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Z.","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sabina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131271","article-title":"Risk of recurrent cancer-associated venous thromboembolism: A Danish nationwide cohort study","volume":"390","author":"Ording","year":"2023","journal-title":"Int J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemostasis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"JCO"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"JCO"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemostasis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active Malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemostasis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","volume-title":"Cochrane handbook for systematic reviews of interventions, version 6.5","author":"Higgins","year":"2024"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1690984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:17:46Z","timestamp":1766121466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1690984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1690984"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1690984","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1690984"}}